NAP: Competition (2007)
Below PR, Mora-Rodriguez R, Gonzalez-Alonso J, Coyle EF. Fluid and carbohydrate ingestion independently improve performance during 1h of intense exercise. Med Sci Sports Exerc. 1995; 27 (2): 200-210.
PubMed ID: 7723643
- Recruitment: Eight endurance-trained subjects completed the study, gave written informed consent and were financially compensated
- Design: Randomized crossover trial. Experimental trials were chosen to fit a factorial design to evaluate the main effects of two factors and the potential interaction between them.
- Blinding used: Double-blind. Prior to participation, the subjects were told they would be recieving four different performance-enhancing treatments. Experimenter did not know which treatment the subjects were getting at each of the four trials.
Intervention
Preliminary Testing
Subjects underwent preliminary testing on a cycle ergomenter to determine VO2max and blood lactate threshold (LT). All subjects also completed a heat acclimation protocol consisting of four one-hour cycling bouts performaed in a warm environment over a 10-day period. The final acclimation bout was completed at a work rate which elicited a VO2 of 5% above LT and was used to faliliarize the subjects with the experimental procedures and to measure the individuals' sweat rate for calculation of fluid replacement volumes during trials.
Experimental Design
- Subjects reported to the lab at the same time of day, fasted and euhydrated
- Subjects consumed similar diets the day before each trial and refrained from exercise
- Upon arrival, subjects had esophageal and rectal thermometers inserted in addition to a catheter into an antecubital vein
- Subjects cycled continuously on a stationary ergometer for 50 minutes in a warm room at a constant work rate that elicited a VO2 of 5% above their LT on four different occasions that were separated by at least 72 hours
- During these exercise bouts, the subjects randomly received
- Fluid and carbohydrates in the form of a 6% CHO electrolyte solution (Gatorade)
- Fluid in the form of a water-electrolyte solution
- Carbohydrates in the form of a 40% maltodextrin electrolyte solution
- Placebo capsles containing electrolytes.
- Carbohydrates given in each of the CHO trials was 79±4g
- Electrolyte content for each trial averaged 619±29mg of sodium and 141±7mg of potassium.
Performance Testing
- Follwing the 50-minute period of constant work, subjects began a cycling performance test, which required the completion of a set amount of work in the shortest time possible
- Subjects had to maintain an intensity elicing a VO2 of 10% above his LT.
Statistical Analysis
- Data collected before treatments were administered were analyzed using one-way ANOVA with repeated measures
- Data of the exercise bouts collected and repeated over time were analyzed using a three-way ANOVA with repeated measures
- Measurements made only once used a two-way ANOVA with repeated measures
- Giesser-Greenhouse or Box adjustment procedures were applied to all F tests
- Differences between means were uncovered with Tukey's HSD post-hoc procedure
- P<0.05.
Timing of Measurements:
- Immediately Pre and Post - Nude weight was measured
- Drinking schedule was immediately before, at 15 minutees, at 25 minutes, and 34 minutes.
- During the 50 min steady state test each of the following was measured every 10 min: skin temp, esophageal temp, heart rate, RPE
- During the 50 min steady state test each of the following was measured every 5 min: oxygen consumption, RER
- The cardic output was measured in triplicate during an 8min period beginning at 34 min of exercise
- A 10 ml blood sample was drawn at 7,25, and 50 min of exercise
- Immediately upon cessation of the performance test the following were measured: skin temp, esophageal temp, rectal temp, HR, 10 mL blood sample drawn
Dependent Variables
- Body Temperature: Esophageal termistor, Rectal thermistor, Surface Thermistor
- Oxygen Consumption: Daniels valve and dry gas meter
- Cardiac Output: CO2 rebreathing technique of Collier using the Fick equation
- Sweat Rate: Loss of nude body weight
- Blood analysis: Serum sodium, plasma glucose, plasma lactate, plasma insulin
Independent Variables:
- Fluid and Carbohydrate in the form of a 6% CHO electrolyte solution (gatorade)
- Fluid in the form of a water-electrolyte solution
- Carbohydrate in the form of a 40% maltodextrin electrolyte solution
- Placebo capsles containing electrolytes
- Carbohydrate given in each of the CHO trials was 79+ 4g
- Electrolyte content for each trials averaged 619 + 29 mg of sodium and 141 + 7 mg of potassium
Control Variables:
- Temperature of the room and % of VO2 exercise intensity
- Initial N: Eight endurance-trained males
- Attrition (final N): Eight
- Age: 23±1
- Ethnicity: Not mentioned.
Anthropometrics
- Weight: 70.6±3.0kg
- VO2: 4.44±0.08 1*min-1
Location
- Texas.
Variables |
Placebo
|
Carbohydrate
|
Fluid | Fluid + Carbohydrate |
Statistical Significance of Group Difference |
Oxygen Consumption (l*min -1) |
3.52±0.08 |
3.52±0.08 |
3.52±0.08 |
3.52±0.08 |
No significant difference |
Hydration Status Sweat Rate (l/h) |
1.33±0.08 |
1.25±0.08 |
1.35±0.08 | 1.32±0.07 |
No significant difference |
Performance Test |
10.92±0.32 |
10.93±0.32 |
9.93±0.28 | 10.22±0.27 |
CHO significantly faster than NO CHO and the fluid + CHO was significantly faster than the carbohydrates-alone |
Cardiovascular Response (HR post b/min-1) | 179±3 |
- The main finding is that both fluid replacement and carbohydrate ingestion individually, improve high-intensity cycling performance
- Performance times were improved by an equal magnitude when subjects consumed either fluid or carbohydrates, in comparison to a placebo. Furthermore, when both fluid and carbohydrates were combined, performance was improved two-fold in comparison to the placebo.
- Therefore, the ingestion of carbohydrates and fluid can significantly improve cycling performance in comparison to the ingestion of only water.
Industry: |
|
||
University/Hospital: | University of Texas at Austin |
- Inclusion/exclusion criteria and recruitment methods not well defined.
- A good effort was taken to control the study but still maintain a real life situation. I think that these studyies should use a 24 hour recall or some other method to assess overall carbohydrate consumption.
Quality Criteria Checklist: Primary Research
|
|||
Relevance Questions | |||
1. | Would implementing the studied intervention or procedure (if found successful) result in improved outcomes for the patients/clients/population group? (Not Applicable for some epidemiological studies) | Yes | |
2. | Did the authors study an outcome (dependent variable) or topic that the patients/clients/population group would care about? | Yes | |
3. | Is the focus of the intervention or procedure (independent variable) or topic of study a common issue of concern to dieteticspractice? | Yes | |
4. | Is the intervention or procedure feasible? (NA for some epidemiological studies) | Yes | |
Validity Questions | |||
1. | Was the research question clearly stated? | Yes | |
1.1. | Was (were) the specific intervention(s) or procedure(s) [independent variable(s)] identified? | Yes | |
1.2. | Was (were) the outcome(s) [dependent variable(s)] clearly indicated? | Yes | |
1.3. | Were the target population and setting specified? | Yes | |
2. | Was the selection of study subjects/patients free from bias? | ??? | |
2.1. | Were inclusion/exclusion criteria specified (e.g., risk, point in disease progression, diagnostic or prognosis criteria), and with sufficient detail and without omitting criteria critical to the study? | No | |
2.2. | Were criteria applied equally to all study groups? | ??? | |
2.3. | Were health, demographics, and other characteristics of subjects described? | Yes | |
2.4. | Were the subjects/patients a representative sample of the relevant population? | ??? | |
3. | Were study groups comparable? | Yes | |
3.1. | Was the method of assigning subjects/patients to groups described and unbiased? (Method of randomization identified if RCT) | Yes | |
3.2. | Were distribution of disease status, prognostic factors, and other factors (e.g., demographics) similar across study groups at baseline? | Yes | |
3.3. | Were concurrent controls or comparisons used? (Concurrent preferred over historical control or comparison groups.) | Yes | |
3.4. | If cohort study or cross-sectional study, were groups comparable on important confounding factors and/or were preexisting differences accounted for by using appropriate adjustments in statistical analysis? | N/A | |
3.5. | If case control study, were potential confounding factors comparable for cases and controls? (If case series or trial with subjects serving as own control, this criterion is not applicable.) | N/A | |
3.6. | If diagnostic test, was there an independent blind comparison with an appropriate reference standard (e.g., "gold standard")? | N/A | |
4. | Was method of handling withdrawals described? | Yes | |
4.1. | Were follow-up methods described and the same for all groups? | N/A | |
4.2. | Was the number, characteristics of withdrawals (i.e., dropouts, lost to follow up, attrition rate) and/or response rate (cross-sectional studies) described for each group? (Follow up goal for a strong study is 80%.) | N/A | |
4.3. | Were all enrolled subjects/patients (in the original sample) accounted for? | Yes | |
4.4. | Were reasons for withdrawals similar across groups? | N/A | |
4.5. | If diagnostic test, was decision to perform reference test not dependent on results of test under study? | N/A | |
5. | Was blinding used to prevent introduction of bias? | Yes | |
5.1. | In intervention study, were subjects, clinicians/practitioners, and investigators blinded to treatment group, as appropriate? | Yes | |
5.2. | Were data collectors blinded for outcomes assessment? (If outcome is measured using an objective test, such as a lab value, this criterion is assumed to be met.) | No | |
5.3. | In cohort study or cross-sectional study, were measurements of outcomes and risk factors blinded? | N/A | |
5.4. | In case control study, was case definition explicit and case ascertainment not influenced by exposure status? | N/A | |
5.5. | In diagnostic study, were test results blinded to patient history and other test results? | N/A | |
6. | Were intervention/therapeutic regimens/exposure factor or procedure and any comparison(s) described in detail? Were interveningfactors described? | Yes | |
6.1. | In RCT or other intervention trial, were protocols described for all regimens studied? | Yes | |
6.2. | In observational study, were interventions, study settings, and clinicians/provider described? | N/A | |
6.3. | Was the intensity and duration of the intervention or exposure factor sufficient to produce a meaningful effect? | Yes | |
6.4. | Was the amount of exposure and, if relevant, subject/patient compliance measured? | Yes | |
6.5. | Were co-interventions (e.g., ancillary treatments, other therapies) described? | N/A | |
6.6. | Were extra or unplanned treatments described? | N/A | |
6.7. | Was the information for 6.4, 6.5, and 6.6 assessed the same way for all groups? | N/A | |
6.8. | In diagnostic study, were details of test administration and replication sufficient? | N/A | |
7. | Were outcomes clearly defined and the measurements valid and reliable? | Yes | |
7.1. | Were primary and secondary endpoints described and relevant to the question? | Yes | |
7.2. | Were nutrition measures appropriate to question and outcomes of concern? | Yes | |
7.3. | Was the period of follow-up long enough for important outcome(s) to occur? | N/A | |
7.4. | Were the observations and measurements based on standard, valid, and reliable data collection instruments/tests/procedures? | Yes | |
7.5. | Was the measurement of effect at an appropriate level of precision? | Yes | |
7.6. | Were other factors accounted for (measured) that could affect outcomes? | Yes | |
7.7. | Were the measurements conducted consistently across groups? | Yes | |
8. | Was the statistical analysis appropriate for the study design and type of outcome indicators? | Yes | |
8.1. | Were statistical analyses adequately described and the results reported appropriately? | Yes | |
8.2. | Were correct statistical tests used and assumptions of test not violated? | Yes | |
8.3. | Were statistics reported with levels of significance and/or confidence intervals? | Yes | |
8.4. | Was "intent to treat" analysis of outcomes done (and as appropriate, was there an analysis of outcomes for those maximally exposed or a dose-response analysis)? | N/A | |
8.5. | Were adequate adjustments made for effects of confounding factors that might have affected the outcomes (e.g., multivariate analyses)? | Yes | |
8.6. | Was clinical significance as well as statistical significance reported? | Yes | |
8.7. | If negative findings, was a power calculation reported to address type 2 error? | N/A | |
9. | Are conclusions supported by results with biases and limitations taken into consideration? | Yes | |
9.1. | Is there a discussion of findings? | Yes | |
9.2. | Are biases and study limitations identified and discussed? | Yes | |
10. | Is bias due to study's funding or sponsorship unlikely? | Yes | |
10.1. | Were sources of funding and investigators' affiliations described? | Yes | |
10.2. | Was the study free from apparent conflict of interest? | Yes | |